



**International Study of Comparative Health Effectiveness with
Medical and Invasive Approaches - Chronic Kidney Disease
Primary Report of Clinical Outcomes**

Funded by the National Heart, Lung, and Blood Institute

Sripal Bangalore, MD, MHA

NYU School of Medicine

On behalf of the ISCHEMIA-CKD Research Group

ISCHEMIA-CKD Research Question

- In stable patients with advanced CKD and at least moderate ischemia on a stress test, is there a benefit to adding cardiac catheterization and, if feasible, revascularization to optimal medical therapy?


CKD Patients are Under-Represented in Contemporary Revascularization vs. Medicine SIHD Trials

2007



eGFR <30: **16** Subjects

2009




Subjects with serum Cr >2 mg/dl **excluded**

2012

FAME 2 Trial

Serum Cr >2 mg/dl: **20** subjects

Study Design



Bangalore et al. Am Heart J. 2018

Eligibility Criteria

Key Inclusion Criteria

- At least moderate ischemia on an exercise or pharmacologic stress test (site determined)
- End-stage renal disease on dialysis or estimated glomerular filtration rate (eGFR) $<30\text{mL}/\text{min}/1.73\text{m}^2$

Key Exclusion Criteria

- Left ventricular ejection fraction $<35\%$
- NYHA class III-IV heart failure
- Unacceptable level of angina despite maximal medical therapy
- ACS within the previous 2 months
- PCI or CABG within the previous 12 months


Optimizing Revascularization

Customized Hydration



LVEDP based (POSEIDON trial)

Heart/Kidney Team



Cardiology/Nephrology/CV surgery

Ultra low/Zero Contrast PCI

Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study

Ziad A. Ali^{1,2*}, Keyvan Karimi Galougahi¹, Tamim Nazif^{1,2}, Akiko Maehara^{1,2}, Mark A. Hardy³, David J. Cohen⁴, Lloyd E. Ratner³, Michael B. Collins^{1,2}, Jeffrey W. Moses^{1,2}, Ajay J. Kirtane^{1,2}, Gregg W. Stone^{1,2}, Dimitri Karpaliotis^{1,2}, and Martin B. Leon^{1,2}

¹Division of Cardiology, Center for Interventional Vascular Therapy, New York Presbyterian Hospital and Columbia University, New York, NY, USA; ²Cardiovascular Research Foundation, New York, NY, USA; ³Department of Surgery, New York Presbyterian Hospital and Columbia University, New York, NY, USA; and ⁴Division of Nephrology, New York Presbyterian Hospital and Columbia University, New York, NY, USA

Received 21 December 2015; revised 10 January 2016; accepted 3 February 2016

Aims	The feasibility, safety, and clinical utility of percutaneous coronary intervention (PCI) without radio-contrast medium in patients with advanced chronic kidney disease (CKD) are unknown. In this series, we investigated a specific strategy for 'zero contrast' PCI with the aims of preserving renal function and preventing the need for renal replacement therapy (RRT) in patients with advanced CKD.
Methods and results	A total of 31 patients with advanced CKD [creatinine = 4.2 mg/dL, inter-quartile range (IQR) 3.1–4.8, estimated glomerular filtration rate = 16 ± 8 mL/min/1.73 m ²] who had clinical indication for PCI based on a prior minimal contrast coronary angiogram were included. Zero contrast PCI was performed at least 1 week after diagnostic angiography using real-time intravascular ultrasound (IVUS) guidance, with pre- and post-PCI measurements of fractional flow reserve and coronary flow reserve to confirm physiological improvement. This approach resulted in successful PCI, no major adverse cardiovascular events and preservation of renal function without the need for RRT within a follow-up time of 79 days (IQR 33–207) in all patients.
Conclusion	In patients with advanced CKD who require revascularization, PCI may safely be performed without contrast using IVUS and physiological guidance with high procedural success and without complications.
Keywords	Percutaneous coronary intervention • Chronic kidney disease • Contrast-induced nephropathy • Intravascular ultrasonography • Coronary physiology

Endpoints

Primary Endpoint

- Time to death or MI

Major Secondary Endpoints

- Time to Death, MI, Hospitalization for Unstable Angina, Heart Failure or Resuscitated Cardiac Arrest
- Quality of Life (separate presentation)

Safety Outcomes

- Composite of initiation of maintenance dialysis or death
- Initiation of maintenance dialysis

Statistical Considerations


Power Calculation (N = 777)

- >80% power to detect 22% to 24% relative reduction in primary endpoint assuming an aggregate 4-year cumulative rate of approximately 41% to 48%

Pre-Specified Statistical Analysis

- Intention-to-treat
- Nonparametric cumulative event rates accounting for competing risks
- Cox regression, covariate-adjusted
 - Emphasize nonparametric event rates if proportional hazards assumption is violated
- Bayesian analysis
 - Evaluate the probability of possible hypotheses/conclusions in light of a set of minimally informative prior probabilities and the current study data

Patient Flow



Key Baseline Characteristics


Characteristic	Total (N=777)	INV (N=388)	CON (N=389)
Age at Enrollment (yrs.)			
Median (25th, 75th)	63 (55, 70)	62 (55, 69)	64 (56, 70)
Female Sex (%)	31	31	31
Hypertension (%)	92	90	93
Diabetes (%)	57	58	56
Prior heart failure (%)	17	17	18
Ejection Fraction			
Median (25th, 75th)	58 (50, 64)	58 (50, 63)	58 (50, 64)
ESRD on Dialysis (%)	53	51	56
Duration of Dialysis (years)	2.0 (1.0, 5.0)	3.0 (1.0, 6.0)	2.0 (1.0, 4.0)
Type of Dialysis			
Hemodialysis (%)	84	83	85
Peritoneal dialysis (%)	15	16	13
eGFR among those not on dialysis			
<15 ml/min/1.73m ² (%)	14	15	13
15 to <30 ml/min/1.73m ² (%)	86	85	87

Key Stress Test and Angiographic Characteristics

Characteristic	Total (N=777)	INV (N=388)	CON (N=389)
Stress Test Modality			
Stress Imaging (%)	82	81	82
Non-imaging ETT (%)	18	19	18
Stress Test Severity (site determined)			
Severe (%)	38	36	39
Moderate (%)	62	64	61
Number of Native Vessels With \geq 50% Stenosis (QCA)			
0 (%)		26	
1 (%)		22	
2 (%)		28	
3 (%)		23	
Specific Native Vessels With \geq 50% Stenosis (QCA)			
Left Main		2	
Left Anterior Descending (LAD)		57	
Proximal LAD		21	
Left Circumflex		44	
Right Coronary artery		45	





Risk Factor Management

No between group differences INV vs CON




High Level of Medical Therapy Optimization is defined as a participant meeting all of the following goals: LDL < 70 mg/dL and on any statin, systolic blood pressure < 140 mm/Hg, aspirin or other antiplatelet or anticoagulant and not smoking. High level of medical therapy optimization is missing if any of the individual goals are missing.

Medications




Coronary Angiography and Revascularization*

Coronary Angiography




Revascularization



*Not preceded by endpoint event

Primary End Point

Death or MI




Subjects at Risk

	0	1	2	3	4
CON	389	330	213	91	13
INV	388	323	190	80	18



Major Secondary End Point

Death, MI, Hospitalization for Unstable Angina or Heart Failure or Resuscitated Cardiac Arrest



Subjects at Risk

CON 389
INV 388

326
315

206
183


87
77

13
18




Secondary End Points

Death




CV Death




Secondary End Points

Myocardial Infarction




Secondary End Points

Procedural MI




Spontaneous MI




Secondary End Points

Unstable Angina




Heart Failure




Secondary End Point

Stroke




Safety End Points*

Death or New Dialysis




New Dialysis



* In those not on dialysis at baseline


Heterogeneity of Treatment Effect

Death or MI



Heterogeneity of Treatment Effect

Death, MI, Hospitalization for Unstable Angina or Heart Failure or Resuscitated Cardiac Arrest



Study Limitations

- Low rates of revascularization in the invasive arm
 - Sensitivity and specificity of stress testing in CKD cohort is poor
 - No requirement for CCTA in the trial
- Based on exclusion criteria, the trial results do not apply to patients with:
 - Acute coronary syndromes within 2 months
 - Highly symptomatic patients
 - LVEF <35%
- Sites were specifically trained to minimize risk of AKI after cardiac catheterization and revascularization.
 - Trial findings not generalizable to centers with higher complication rates

Conclusions

- Largest trial of invasive vs. conservative strategy in patients with advanced CKD and SIHD
- Low rates of procedural complications (stroke, AKI)
- Overall, an initial invasive strategy did not demonstrate a reduced risk of clinical outcomes as compared with an initial conservative strategy

We thank the investigators, the study coordinators and especially the participants in the trial

NHLBI

Jerome L. Fleg
Ruth Kirby

Steering Committee

Sripal Bangalore
Judith Hochman (ISCHEMIA trial Chair)
David Maron (ISCHEMIA trial Co-Chair)
Glenn Chertow
William Boden
Bruce Ferguson
Robert Harrington
Gregg Stone
David O. Williams

Renal Committee

Charles Herzog
David Charytan
Glenn Chertow
Peter McCullough
Roxana Mehran
Carlo Briguori

CCC Faculty

Jeffrey Berger
Roy Mathew
Jonathan Newman
Harmony R. Reynolds
Mandeep Sidhu

CCC

Stephanie Mavromichalis
Gia Cobb
Stephanie Ferket **
Andre Gabriel**
Diana Cukali**
Kevin McMahon**
Ahmed Ayoub**
Matthew Shinseki**
Paula Wilson**
Solomon Yakubov**
Mark Xavier

SDCC

Sean O' Brien
Frank Rockhold
Sam Broderick
Zhen Huang
Lisa Hatch
Wayne Pennachi
Khaula Baloch
Michelle McClanahan-Crowder
Matthew Wilson
Jeff Kanters
Dimitrios Stournaras
Allegra Stone
Linda Lillis

Site PIs (≥10 randomized)

Alexander M. Chernyavski
Alexander Borisov (N)
Tomasz Mazurek
Carlo Briguori

Leo A. Bockeria
Evgeny Shutov (N)
Mayil S. Krishnam
Kevin T. Harley (N)
Wei Ling (N)
Piotr Pruszczyk
Marcin Demkow
Robert Malecki (N)
Juan Manuel López Quijano
Alejandro Chevaile Ramos (N)
Patricia Pellikka
Kian-Keong Poh
Titus Lau (N)
Michael Chobanian (N)
Shao-ping Nie
Jiyan Chen
Xin Fu
Shuyang Zhang
Chakkanalil Sajeev
Atul Mathur
Eapen Punnoose
Ranjan Kachru
Kevin Baine
Harmony Reynolds
Kreton Mavromatis
Aleksandras Laucevicius
Andras Vertes
Jorge Escobedo
Anjali Acharya
Melemadathil Srilatha (N)
Hong Cheng (N)
Wei Ling Lau (N)
Alejandro Chevaile (N)

Neesh Pannu (N)
Zhiming Ye (N)
LaTonya Hickson (N)
Olga Zhdanova (N)
Zhangsuo Liu (N)
Ajit Narula (N)
Harold Franch (N)
Kishore Dharan (N)
Bidhun Kuriakose (N)
Satish Sankaranarayanan (N)
Marius Miglinas (N)
Xuemei Li (N)
Sanjeev Gulati (N)
SC Tiwari (N)
Titus Lau (N)
Peter Voros (N)
Maria Juana Perez Lopez (N)

Angiographic Core Lab

Ziad Ali
Philippe Genereux
Maria A. Alfonso
Michelle Cinguina
Maria P. Corral
Nicoleta Enache
Javier J. Garcia
Katharine Garcia
Jennifer Horst
Ivana Jankovic
Maayan Konigstein
Mitchel B. Lustre
Yolayfi Peralta
Raquel Sanchez

ECG/ETT Core Lab

Bernard Chaitman
Bandula Guruge
Jane Eckstein
Mary Streif

CEC

Bernard Chaitman
Salvador Cruz-Flores
Eli Feen
Mario J. Garcia
Lisa Alderson
Eugene Passamani
Maarten Simoons
Hicham Skali
Kristian Thygesen
David Waters
Ileana Pina

Device donations:

Abbott Vascular
Medtronic, Inc.
St. Jude Medical, Inc.
Phillips Co.
Omron Healthcare, Inc




Country Leaders


Country	Lead Cardiologist	Lead Nephrologist
Argentina	Dr. Luis Guzman	Dr. Rafael Maldonado
Australia	Dr. Joseph Selvanayagam	Dr. Magid Fahim
Austria	Dr. Herwig Schulenz	
Belgium		Dr. Kathleen Claes
Brazil	Dr. Renato Lopes	Dr. Maria Eugenia Canziani and Dr. Sergio Draibe
Canada	Dr. Akshay Bagai and Dr. Kevin Bainey	Dr. Ron Wald
China	Dr. Lixin Jiang	Dr. Xuemei Li
France	Dr. Emmanuel Sorbets	Dr. Eric Daugas
Germany	Dr. Rolf Doerr	
Hungary	Dr. Andras Vertes	Dr. Peter Voros
India	Dr. Balram Bhargava	Dr. Sandeep Mahajan
Italy	Dr. Francesco Orso	
Lithuania	Dr. Jelena Celutkiene	Dr. Marius Miglinas
Macedonia	Dr. Sasko Kedev	
Mexico	Dr. Jorge Escobedo	Dr. Magdalena Madero
New Zealand	Dr. Gerard Devlin	Dr. Peter Sizeland
Peru	Dr. Walter Mogrovejo	Dr. Luis Orrego Guerrero
Poland	Dr. Radek Pracon and Dr. Marcin Demkow	Dr. Robert Malecki
Portugal	Dr. Ruben Ramos	Dr. Fernando Nolasco
Russia	Dr. Olga Bockeria	Dr. Evgeny Shutov
Serbia	Dr. Branko Beleslin	Dr. Sanja Simic Ogrizovic
Singapore	Dr. Kian Keong Poh	Dr. Titus Lau
Spain	Dr. Almudena Castro	Dr. Rafael Selgas
Sweden	Dr. Claes Held	
Thailand	Dr. Srun Kuansapert	Dr. Kajornsak Noppakun
UK	Dr. David Wheeler	
US-VA/North Region	Dr. Mandeep Sidhu	Dr. Roy Mathew



Coronary Angiography and Revascularization in CON



Reasons for No Cardiac Catheterization in Invasive



Reasons for No Revascularization after Cath in INV

